Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Virginia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Virginia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Virginia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Charles Maurer (NPI 1386675999)

Field	Value
Entity Type	Individual
Organization	Charles Maurer
Address	4501 Empire Court
City	Fredericksburg
State	VA
ZIP	22408
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 5, 2006

Payer Source	Total Paid
Medicare	$2.8M
Medicaid	$0

Key Findings

This provider’s billing is effectively single-payer: Total Medicare revenue is $2.8M and there is no Medicaid billing on file, so Medicare drives the entire documented public-payer footprint for this NPI. That concentration means analyses and network negotiations should treat this entity as Medicare-dependent rather than balanced across public programs.

Revenue is highly concentrated in a few high-cost oncology drugs: the top three Medicare codes account for 46.8% of this provider’s total Medicare revenue, led by J9271 $498.8K (18.9%), J9299 $472.3K (17.9%), and J9144 $266.8K (10.1%). This level of concentration signals that monoclonal antibody / immunotherapy infusions are the principal revenue drivers.

The provider’s taxonomy (Hematology & Oncology) and CPT/J-code mix indicate an infusion-centered oncology practice that delivers systemic cancer therapies and supportive agents on-site. High-revenue drug codes such as J9271, J9299 and J9144 plus chemotherapy and infusion procedure codes like 96413 ($54.3K) and 96367 ($21.1K) show routine administration of IV anticancer drugs and prolonged infusion sessions.

Competitive standing on flagship drugs is modest to typical rather than dominant: J9271 ranks #990 of 1841 (45th percentile; typical, unremarkable volume), J9299 ranks #171 of 505 (66th percentile; typical, unremarkable volume), and J9144 ranks #362 of 615 (39th percentile; typical, unremarkable volume). In short, this practice is a steady regional participant in high-cost immunotherapies but not a national leader for those agents.

There are several statistical outliers in the non-drug service mix that suggest above-typical procedural and office visit intensity: 99214 is labeled an extreme outlier (ranks #8500 of 479517, 98th percentile; extreme outlier, far above typical national volume), J1439 is labeled notably above typical (ranks #51 of 1209, 96th percentile; notably above typical national volume), and codes such as 96413 and 96367 are also described as notably above typical. These high-percentile procedural and E/M signals imply heavier on-site management and follow-up relative to many peers.

Supportive-care and biosimilar utilization comprise a meaningful portion of drug revenue and reflect typical oncology supportive patterns: J0897 (denosumab) generated $241.9K (9.1%), J1569 (immune globulin) generated $227.5K (8.6%), and biosimilars such as Q5122 ($42.4K) and Q5119 ($33.9K) are present in the mix. The presence of multiple bone-modifying agents, immune globulin, and growth-factor biosimilars indicates bundled supportive-care services alongside anti-cancer therapies.

Ancillary diagnostic and practice-supply codes show in-office capacity for laboratory monitoring and phlebotomy that supports routine oncology care: 85025 (CBC) accounts for $21.6K (0.8%), 80053 (CMP) $19.7K (0.7%), 36415 (phlebotomy) $16.7K (0.6%), and 88185 (flow cytometry add-on) $11K (0.4%). These volumes align with an infusion clinic that performs its own blood draws and basic lab panels for treatment monitoring.

This NPI has long tenure in the Medicare program (NPI enumerated 2006-07-05, ~20 years ago), which supports a hypothesis of established referral relationships and operational stability. Given the tenure and the concentrated revenue base, payer strategy or network alignment discussions should focus on infusion service terms and reimbursement for high-cost immunotherapies.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

93 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	11,600	$40	$498.8K
J9299	Injection, nivolumab, 1 mg	19,680	$20	$472.3K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,020	$40	$266.8K
J1930	Injection, lanreotide, 1 mg	5,760	$40	$253.4K
J0897	Injection, denosumab, 1 mg	13,440	$20	$241.9K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	6,320	$40	$227.5K
J1439	Injection, ferric carboxymaltose, 1 mg	107,250	$1	$107.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,120	$90	$104.4K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	2,110	$30	$54.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	550	$100	$54.3K

Showing 1–10 of 93

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 93 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Virginia Distribution

Charles Maurer — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Virginia

Full comparison — all codes billed, vs. state median

93 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	64	110	12,800	$40	$610.9K
J9299	6	30	12,920	$20	$335.4K
J9144	35	60	8,280	$40	$332.7K
J1930	2	10	3,840	$40	$188.7K
J1569	4	30	3,000	$40	$135.7K
J0897	20	340	2,820	$20	$89.3K
J9264	8	10	6,800	$10	$86.1K
J1449	3	10	2,640	$30	$66.9K
Q5119	20	40	1,570	$20	$39.6K
88185	32	60	620	$20	$34.3K

Showing 1–10 of 93

Related Providers

Other providers that share a Tax Identification Number (TIN) with Charles Maurer, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Wilfredo Blasini	FL	Clinical Pathology Physician	$16.9M	$307.9K
Ryan Olson	FL	Anatomic Pathology & Clinical Pathology Physician	$12.8M	$80
American Oncology Partners PA	OH	Hematology & Oncology Physician	$0	$11.8M
Robert Mcdonald	AZ	Diagnostic Radiology Physician	$7.5M	$0
David Smith	MD	Hematology & Oncology Physician	$6.4M	$0
Stephen Divers	AR	Hematology & Oncology Physician	$3.9M	$1.5K
Robert Muldoon	AR	Hematology & Oncology Physician	$3.2M	$0
Bradley Sumrall	GA	Medical Oncology Physician	$3.1M	$0
Linda Hendricks	GA	Specialist	$3.1M	$0

Nearby Providers

Other providers in the same ZIP code as Charles Maurer, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Compass Counseling Services Of Northern Virginia	VA	Community/Behavioral Health Agency	$0	$54.4M
Spotsylvania Medical Center Inc	VA	General Acute Care Hospital	$0	$31M
Pinnacle Treatment Centers Va-i, LLC	VA	Methadone Clinic	$152.9K	$15.6M
Assured Corporation	VA	Home Health Agency	$0	$12.8M
Lakshminarayanan Nandagopal	VA	Hematology & Oncology Physician	$2.9M	$0
Bonny Moore	VA	Hematology & Oncology Physician	$2.7M	$0
Matthew Whitehurst	VA	Medical Oncology Physician	$2.1M	$0
Sudeep Menachery	VA	Hematology & Oncology Physician	$1.9M	$0
Arijit Chanda	VA	Interventional Cardiology Physician	$571.6K	$0
Anh Vu	VA	Cardiovascular Disease Physician	$549.9K	$90

Charles Maurer — Billing Profile & Reimbursement Data

Sign up for Charles Maurer — Billing Profile & Reimbursement Data policy alerts

Charles Maurer — Billing Profile & Reimbursement Data

Sign up for Charles Maurer — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References